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Serum albumin is a strong predictor of death in chronic dialysis
patients
KuNIT0sHI ISEKI, NOBUYUKI KAWAZOE, and KosHIRo FUKIYAMA
Third Department of Internal Medicine, School of Medicine, University of The Ryukyus, Okinawa, Japan
Serum albumin is a strong predictor of death in chronic dialysis
patients. We examined the predictive value of various clinical variables
in assessing survival in chronic hemodialysis patients (N = 1,243, 524
females, 719 males) who were under treatment with hemodialysis as of
January 1991 in Okinawa, Japan and who were followed up until April
1992. Basal clinical data such as sex, starting date of dialysis, primary
renal disease, blood pressure, blood chemistry values, and dialysis
prescription data obtained just prior to dialysis were registered at the
start of the study. As of the end of April 1992, 104 had died, 16 were
transplant recipients, and five had been transferred. Those who died
had significantly lower levels of total protein, serum albumin, total
cholesterol, triglyceride, BUN, serum creatinine, body weight, body
height, diastolic blood pressure, and duration of hemodialysis than
those who survived. Older patients and those with diabetes mellitus had
a poorer prognosis. A forward stepwise logistic procedure by SAS was
used to determine the predictive value of the above clinical variables.
With the addition of laboratory variables, the predictive value of
diabetes was lost, as the diabetic patients had low serum levels of
albumin and creatinine. The standardized coefficient was —0.380 (P =
0.0001) at age of entry, 0.316 (P = 0.0001) for serum albumin, 0.280 (P
= 0.0001) for serum creatinine, 0.138 (P = 0.043) for body mass index
(BMI), and —0.139 (P = 0.016) for male sex. The prescribed dialysis
dose (M2 hrper week) was significantly correlated with serum creatinine(r = 0.48, P = 0.0001), serum albumin (r = 0.135, P = 0.0001) and BMI(r = 0.275, P = 0.0001). Serum albumin was found to be a strong
predictor of death in chronic hemodialysis patients. Causes of low
serum albumin should be carefully evaluated if underlying illness is not
evident.
Several retrospective studies of survival in patients receiving
maintenance hemodialysis have been conducted [1—3]. How-
ever, no predictors of mortality other than age at start of
dialysis and diabetes mellitus have been identified. Measure-
ment of predialysis BUN and KT/V has been used to monitor
the amount of dialysis [4, 5] and, consequently, the use of short
dialysis was introduced. Short dialysis may result in underdial-
ysis and is associated with poor outcome [6, 71. In fact, the
reported frequency of underdialysis is high, especially in those
on shortened dialysis [8]. However, the use of shortened
dialysis was based on the result obtained in the National
Cooperative Dialysis Study of well patients [9]. These findings
do not apply to the older and sicker patients who are currently
increasingly accepted for dialysis [10] and who are possibly
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malnourished. Lowrie and Lew [4] and others [5] have shown
that nutritional status is a good predictor of mortality in dialysis
patients. However, the role of dialysis prescription has not been
fully evaluated [4]. We therefore conducted a short-term pro-
spective study to identify the nutritional and dialysis prescrip-
tion factors useful in assessing the risk of mortality in patients
receiving maintenance hemodialysis.
We were able to follow a large number of chronic hemodial-
ysis patients. A retrospective analysis of the patients' survival
and a description of the demographics of the population have
been presented previously [11]. We found that age at the start of
dialysis, the year starting dialysis, and the presence of diabetes
mellitus were significant prognostic factors. However, since
these factors are not subject to modification with treatment, we
designed a short-term prospective study to detect those factors,
if any, which are clinically controllable. The results may be
useful in the formulation of therapeutic strategies which would
interdict the abnormalities precipitating death in patients re-
ceiving chronic hemodialysis.
Methods
Between 1971 and 1990, we registered a total of 1,982 patients
who had survived at least one month on scheduled maintenance
dialysis in Okinawa, Japan [11]. Patients who died (N = 605),
underwent renal transplant (N = 75), were transferred (N = 23)
and were placed on CAPD (N = 36) were subsequently ex-
cluded. Therefore, a total of 1,243 patients (524 females, 719
males) were receiving maintenance hemodialysis as of January
1991, the start of the study period. By the end of the study
period, April 1992, 104 patients had died, 16 had undergone
renal transplantation, and five had been transferred. Analysis
was conducted using data for the 1,222 patients (515 females,
707 males) who had not received renal transplantation or been
transferred.
All the medical records were reviewed by one of us (K.I.) and
the following data were obtained: date of birth, sex, date of start
of dialysis, laboratory and clinical data, dialysis prescription,
and status as of April 1992. The laboratory values were ob-
tained before routine hemodialysis in January 1991. Laboratory
and clinical data included body weight, height, blood pressure,
total protein, serum albumin, total cholesterol, triglyceride,
BUN, serum creatinine, and uric acid. Body height was mea-
sured within six months of the start of the study. Body mass
index (B MI) was defined as the ratio of weight to height squared
(kg/rn2). In addition, dialysis prescription data, such as type of
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Table 1. Characteristics of the patients and dialysis prescription
Number of patients
Total
Males
Females
Age at January 1991, years
Mean SEM
Range
Duration of hemo"tlysis treatment, months
Mean SEM
Range
Original renal disease
Chronic glomerulonephntis
Diabetes mellitus
Hypertensive nephrosclerosis
Polycystic kidney disease
Lupus nephritis
Others
Frequency of dialysis per week
once
twice
thrice
Duration of dialysis, hours per session
<3.0
3.0—3.5
3.5—4.0
4.0—5.05.0
Dialyzer membrane area (square meter, m2)
<1.0
1.0—I .4
1.5—1.92.0
Dose of dialysis, m2 hr per week
<10
10—15
15—20
20—25
25—3030
dialyzer, blood flow rate, duration and frequency of dialysis
were obtained. The cause of death was classified into the six
categories: infection, withdrawal, cardiac, sudden death, vas-
cular, or other [6, 11]. No patients were lost to follow-up.
Patients demographics determined at the start of the study
are shown in Table 1. The mean (sEM) age was 52.2 (0.4) years,
ranging from 13 to 91 years old. The mean duration of hemodi-
alysis treatment was 61.9 (1.4) months, ranging from one to 233
months. The original renal diseases were chronic glomerulone-
phritis (N = 839, 67.5%), diabetic nephropathy (N = 211,
17.0%), hypertensive nephropathy (N = 59, 4.7%), polycystic
kidney disease (N = 29, 2.3%), lupus nephritis (N 23, 1.9%),
and other (N = 82, 6.6%). One thousand forty-one patients
(83.7%) were dialyzed three times per week, 191 patients
(15.4%) two times per week, and 11 patients (0.9%) once a
week. The duration of dialysis (hours per session) was 3.0 to 3.5
hours in 65 patients (5.2%), 3.5 to 4.0 hours in 708 (57.0%), 4.0
to 5.0 hours in 125 (10.0%), and more than five hours in 345
(27.8%). The median hours per session was 3.5 to 4.0 hours.
The dialyzer membrane area used (m2) was <1.0 m2 in 60
patients (4.8%), 1.0 to 1.4 m2 in 434(34.9%), 1.5 to 1.9 m2 in 534
(43.0%), and more than 2.0 m2 in 215 (17.3%) (range, 0.7 to 2.2
m2; mean, 1.48 m2 The weekly dialysis dosage, calculated as
(frequency of dialysis) x (duration of dialysis) x (dialyzer
Clinical variables
Died
N = 104
Survived
N = 1,118 P value
Age, years 65.2 (1.2) 52.2 (0.4) 0.0001
Duration of HD, months 45.3 (4.2) 63.4 (1.5) 0.0001
Dose of HD, m2 hr/W 15.6 (0.5) 18.5 (0.2) 0.0001
Body height, meters 1.53 (0.01) 1.57 (0.03) 0.003
Body weight, kg 48.7 (0.9) 53.4 (0.3) 0.0001
Body mass index, kg/rn2 20.6 (2.6) 21.7 (0,1) 0.001
Systolic blood pressure, mm Hg 153.8 (2.6) 151.3 (0.7) NS
Diastolic blood pressure, mm Hg 77.0 (1.2) 81.3 (0.4) 0.001
Total protein, g/dl 6.3(0.1) 6.5(0.1) 0.0001
Serum albumin, g/dl 3.5(0.1) 3.9(0.1) 0.0001
Total cholesterol, mg/dl 158.8 (3.9) 171.9 (1.2) 0.001
Triglyceride, rng/dI 131.3 (8.3) 165,1 (3.5) 0.0003
BUN, mg/dl 78.9 (2.2) 86.4 (0.6) 0.001
Serum creatinine, mg/dl 10.4 (0.3) 13.4 (0.1) 0.0001
Serum uric acid, rng/dl 7.9 (0.2) 8.3 (0.1) NS
Smoker, % 17.3 23.8 NS
Drinker, % 10.6 21.5 0.009
Antihypertensives, % 56.7 51.7 NS
Diabetes mellitus, % 35.6 15.3 0.0001
membrane area) was as <10 m2 hrs in 139 patients (11.2%), 10
to 15 m2 hrs in 289 (23.2%), 15 to 20 m2 hrs in 349 (28.1%), 20
to 25 in2 hrs in 244 (19.6%), 25 to 30 m2 hrs in 134 (10.8%), and
more than 30 m2 hrs in 88 (7.1%) (range, 3.3 to 33.0 m2 hrs;
median, 15 to 30 m2 hrs). The mean (sEM) blood flow rate was
188.3 (0.7) ml/min, ranging from 100 to 300 mI/mm, and the
median blood flow rate was 200 ml/min. Data regarding smoking
and drinking habits and the use of antihypertensive drugs were
also obtained.
Student's t-test and the chi square test were used to compare
data for those who died with that for those who survived.
Variables found to be significant were entered into the logistic
analysis model using a SAS package [11]. The dependent
variable in this model was binary, that is, survival or mortality
at the end of the observation period. A variable was deleted
from the model if it did not meet the 5% significance level.
Pearson correlation coefficients were calculated to examine the
relationship between the pertinent clinical variables. Data are
expressed as mean SEM.
Results
In the 104 patients who died, the cause of death was infection
in 16.3%, withdrawal in 16.3%, cardiac in 28.0%, sudden death
in 7.7%, vascular in 16.3%, and other in 15.4%.
Table 2 shows values of clinical variables in the patients that
died and those that survived. In the deceased group, age was
greater and duration of hemodialysis was shorter, while the
dose of dialysis was lower than that in the survival group. Body
height, weight, and BMI were significantly lower in the former
group. There was no difference between the groups in systolic
blood pressure, but diastolic blood pressure was slightly lower
in the deceased group. Total protein, serum albumin, total
cholesterol, triglyceride, BUN, and serum creatinine were also
lower in the deceased group. The percentage of smokers and
ex-smokers was slightly lower in deceased group. The percent-
age of drinkers and ex-drinkers was significantly lower in the
Table 2. Comparison of clinical variables between patients who died
and those who survived
1,243
719
524
52.2 0.4
13 to 91
61.9 1.4
I to 233
839 (67.5%)
211 (17.0%)
59 (4.7%)
29 (2.3%)
23 (1.9%)
82 (6.6%)
11(0.9%)
191 (15.4%)
1041 (83.7%)
0
65 (5.2%)
708 (57.0%)
125 (10.0%)
345 (27.8%)
60 (4.8%)
434 (34.9%)
534 (43.0%)
215 (17.3%)
139 (11.2%)
289 (23.2%)
349 (28.1%)
244 (19.6%)
134 (10.8%)
88(7.1%)
Parentheses denote SEM. NS, not significant.
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Table 3. Results of the logistic analysis
Variables Stand. coef. Chi-square P
Age in 1991, years —0.3799 26.53 0.0001
Sex (male = 1) —0.1386 4.51 0.0336
Body mass index, kg/rn2 0.1378 4.07 0.0437
Serum albumin, g/dl 0.3161 22.26 0.0001
Serum creatinine, rng/dl 0.2797 13.21 0.0003
Abbreviation Stand coef is standardized coefficient.
deceased group. More than 50% of all patients were prescribed
antihypertensive drugs. The percentage of diabetic patients was
significantly higher in the deceased group (35.6% vs. 15.3%, P
<0.0001 by chi-square test).
Table 3 summarizes the results of the logistic analysis. In
addition to age and male sex, the laboratory variables of serum
albumin, serum creatinine, and body mass index were found to
be significant predictors of death. The prognostic value of
diabetes mellitus was lost with the addition of laboratory
variables, since the diabetics had low levels of serum albumin
and creatinine. Weekly dialysis schedule per se and dose of
dialysis were not significantly associated with mortality in
chronic dialysis patients.
The association between relative risk of death and serum
albumin, creatinine, and BMI values is summarized in Table 4.
The serum albumin values for all patients were distributed as
follows: less than 3.5 g/dl in 16.9%; 3.5 to 3.9 g/dI in 41.1%; 4.0
to 4.4 gIdI in 30.6%; and 4.5 gIdl and over in 11.4%. The crude
death rate in each albumin range was 22.3%, 7.6%, 4.3%, and
2.2%, respectively. The serum creatinine values in all patients
were distributed as follows: less than 10 mg/dl in 17.4%; 10 to
14.9 mgldl in 52.0%; 15.0 to 19.9 mgldl in 29.0%; and 20 mg/dl
and over in 1.6%. The crude death rate in each creatinine range
was 18.8%, 9.0%, 1.1%, and 0%, respectively. The relative risk
of death was lower in patients with higher levels of serum
creatinine. The body mass index was distributed as follows: less
than 21 kg/m2 in 46.6%; 21 to 23.9 kglm2 in 33.4%; and 24 kg/m2
and over in 20.0%. The relative risk of death was lower in
patients with higher BMI.
Table 5 shows the Pearson correlation coefficients for dialysis
dosage and several clinical variables. There was a significant
positive correlation between the dialysis dosage and serum
creatinine, BMI, and duration of dialysis. There was a negative
correlation between dialysis dosage and age.
As shown in Figure 1, there was a significant correlation
between dialysis dosage and serum creatinine (r = 0.482, P =
0.0001).
Discussion
The annual overall mortality rate of patients in our dialysis
registry was about 7% [11], which is lower than others [12—14],
but not the lowest [15]. It is possible that differences among
patient groups in the percentage of diabetic patients, age at
entry, dialysis prescription, and other clinical conditions may
contribute to these results [161. Of the laboratory variables,
serum levels of albumin and creatinine and body mass index
were found to have significant predictive value (Table 3). Other
variables, such as total cholesterol, serum uric acid, BUN, total
protein, and blood pressure, had no significant predictive value.
While a number of other laboratory variables, such as C02,
potassium, phosphate, and calcium, may contribute to survival
[4], these were considered to have less predictive value than
BUN or total cholesterol.
High serum creatinine was associated with low risk of death,
but was also associated with high dialysis dosage. While in-
creased dialysis may lead to greater patient body mass and
generation of creatinine, it is also possible that physicians
consider serum creatinine value and provide dialysis at greater
doses to better nourished patients. If albumin and creatinine
values rather than diabetes mellitus were applied as predictors
of mortality risk, it might be found that the extremely high
mortality associated with diabetes mellitus is related as much to
undernutrition as it is to diabetes mellitus per se [17].
In the Diaphane collaborative study [1], better survival was
found in patients dialyzed three times a week than in those
dialyzed twice a week. Prolonged and slow dialysis was asso-
ciated with 75% survival at 10 years [15]. Underdialysis may
trigger a feedback mechanism decreasing the dietary intake of
nutrients [4], thereby reducing the levels of serum albumin,
and, eventually, of creatinine and body mass index. Lean
patients have a poorer prognosis among both dialysis patients
[1] and hypertensive patients [18], although leanness per se was
not considered to be an independent risk factor [181. However,
we could not exclude the possibility that patients already had
these clinical characteristics before starting hemodialysis ther-
apy and that they were not improved despite adequate dialysis.
Uremia per se [19] and the current practice of prescribing a
low-protein diet to retard the progression of renal failure may
cause malnutrition [20].
Comorbid conditions such as vascular disease. ischemic
heart disease, malignancies, and chronic obstructive pulmonary
disease are risk factors of mortality in dialysis patients [10]. Of
the 123 patients (9.9%) in our group who were hospitalized due
to multiple reasons, 29 (24%) died during the study period. This
rate is significantly higher (chi square value 42.6, P < 0.0001)
than that of patients who were ambulatory at the start of study
(6.7%).
We did not assess the intake of protein in this study. Protein
intake was assumed to be prescribed as recommended, 1.0 to
1.4 g/kg [21, 22], which is lower than that of the general
population in Okinawa [23]. However, it is reported that poor
compliance with dietary and medical advice is quite common in
adult chronic hemodialysis patients [24]. If so, a large number
of dialysis patients may be malnourished, even though they are
ambulatory and their condition stable [4]. Of the patients in our
registry, 58% were hypoalbuminemic (<4.0 gIdl); 2.8% severely
hypoalbuminemic (<3.0 gIdl); Lowrie and Lew [4] reported
66% and 2.0%, respectively. It has been suggested that the
dietary protein intake is affected by the dialysis dosage and can
be increased with more intense dialysis [25, 26]. Therefore,
physicians should be aware of the possibility of inadequate
dialysis treatment as well as of underlying illness which reduces
appetite [27].
Blood pressure was not found to be a significant predictive
factor in our short-term prospective study, in contrast to the
findings in previous studies of dialysis patients [1, 15, 28] and
the general population [29—31]. Since the mean duration of
hemodialysis at the start of study was 61.9 months, the hyper-
tensive patients at risk may have died before study enrollment.
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Fig. 1. Correlation between serum crealinine
and dialysis dosage. The correlation was
significant (r = 0.469, P < 0.001).
Table 4. Crude risk ratios and relative death risks
Variables
Patients Risk
of
death
kelative death risk
Exposed Died To index 95% C.I. P
Albumin, gidi
<3.5 206 46 0.223 1.00
3.5—3.9 501 38 0.076 0.40 0.22—0.58 0.0001
4.0—4.4 373 16 0.043 0.27 0.12—0.41 0.0001
4.5— 139 3 0.022 0.24 0.06—0.48 0.001
Creatinine, mg/dl
<10.0 213 40 0.188 1.00
10.0—14.9 635 57 0.090 0.59 0.34—0.84 0.006
15.0— 373 4 0.011 0.12 0.03—0.21 0.0001
Body mass index kg/rn2
<21.0 570 60 0.105 1.00
21.0—23.9 408 30 0.074 0.98 0.54—1.42 0.596
24.0— 244 14 0.057 0.79 0.35—1.22 0.177
Index risk is the death risk if albumin, creatinine, and BMI are <3.5 g/dl, <10.0 mg/dl, and <21.0 kg/rn2. C.L. denotes confidence interval.
Table 5. Correlation between the dose of dialysis and the several
clinical variables
Clinical variables r P
Serum creatinine, mg/dl 0.482 0.0001
Duration of dialysis, months 0.349 0.0001
Age, years —0.333 0.0001
Body mass index, kg/m2 0.275 0.0001
Serum albumin, g/dl 0.135 0.001
The Pearson correlation coefficient (r) and P values are shown in this
Table.
In fact, the reported peak period of vulnerability (hazard) for
cardiac death is the first four years [6]. Recently it has been
reported that there is little effect of systolic or diastolic hyper-
tension on the short-term survival of hemodialysis patients [32].
However, in our study, about 45% of all deaths were related to
cardiac and vascular events that suggested underlying athero-
sclerosis [33—351.
Of the significant predictors of death, serum albumin and
BMI are correctable. The dosage of dialysis can be increased by
either prolonging the duration of dialysis treatment or using a
larger dialyzer membrane area. In our experience, however,
patients are very reluctant to agree to prolongation of the
treatment time [36].
In summary, we demonstrated in this short-term prospective
study that serum levels of albumin and creatinine and the BMI
are significant predictors of death in maintenance hemodialysis
patients. The dialysis dosage was significantly correlated with
each of these laboratory and clinical variables. The dialysis
prescription should carefully be adjusted in such high-risk
patients. However, the effect of increasing dialysis dosage on
patients survival rate remains to be determined.
Iseki et a!: Prediction of death in dialysis patients 119
Acknowledgments
We acknowledge the contributions of the Okinawa Dialysis Study
(OKIDS) affiliated physicians, clinical staff, and administrative person-
nel. Parts of this study were supported by a grant from The Ministry of
Health and Welfare, titled "Jinfuzen Iryo Kenkyu" coordinated by Dr.
N. Mimura. Registration and processing of the data were done by Mrs.
C. Iseki.
Reprint requests to Dr. Kunitoshi Iseki, M.D., Third Department of
Internal Medicine, University of The Ryukyus, 207 Uehara, Okinawa
903-01, Japan.
References
1. DEGOULET P, LEGRAIN M, REACH I, AIME F, DEvRIE5 C, RoJAs P,
JACOBS C: Mortality risk factors in patients treated by chronic
hemodialysis. Report of the Diaphane collaborative study.
Nephron 31:103—1 10, 1982
2. MAILLOUX LU, BELLUCCI AG, MOSSEY RT, NAPOLITANO B,
MooRE T, WILKES BM, BLUESTONE PA: Predictors of survival in
patients undergoing dialysis. Am J Med 84:855—862, 1988
3. HELLERSTED WL, JOHNSON WJ, ASCHER N, KJELLSTRAND CM,
KNUTSON R, SHAPIRO FL, STERIOFF 5: Survival rates of 2,728
patients with end-stage renal disease. Mayo Clin Proc 59:776—783,
1984
4. Lowiu EG, LEW NL: Death risk in hemodialysis patients: The
predictive value of commonly measured variables and an evalua-
tion of death rate differences between facilities. Am J Kidney Dis
15:458—482, 1990
5. ACCHIARDO SR. MOORE LW, LATOUR PA: Malnutrition as the
main factor in morbidity and mortality of hemodialysis patients.
Kidney mt 24:S199—S203, 1983
6. MAILLOUX LU, BELLUCCI AG, WILKES BM, NAPOLITANO B,
MossEY RT, LESSER M, BLUESTONE PA: Mortality in dialysis
patients: Analysis of the causes of death. Am J Kidney Dis
18:326—335, 1991
7. HELD JH, LEVIN NW, BOVBJERG RR, PAULY MV, DIAMOND LH:
Mortality and duration of hemodialysis treatment. JAMA 7:87 1—
875, 1991
8. GOTCH PA, YARIAN S, KEEN M: A kinetic survey of US hemodi-
alysis prescriptions. Am J Kidney Dis 15:511—515, 1990
9. Lowiu EG, LAIRD NM, PARKER TF, SARGENT JA: Effects of the
hemodialysis prescription on patient morbidity. Report from the
National Cooperative Dialysis Study. N Engl J Med 305:1176-1181,
1981
10. COLLINS AC, HANSON G, UMEN A, KJELLSTRAND C, KESHAVIAN
P: Changing risk factor demographics in end-stage renal disease
patients entering hemodialysis and the impact on long-term mortal-
ity. Am J Kidney Dis 15:422—432, 1990
11. ISEKI K, KAWAZOE N, OSAWA A, FUKIYAMA K: Survival analysis
of dialysis patients in Okinawa, Japan (1971—1990). Kidney mt
43:404—409, 1993
12. ODAKA M: Mortality in chronic dialysis patients in Japan. Am J
Kidney Dis 15:410—413, 1990
13. HELD PJ, BRUNNER F, ODAKA M, GARCIA JR. PORT PK, GAYLIN
DS: Fiveyear survival for end-stage renal disease patients in the
United States, Europe, and Japan, 1982 to 1987. Am J Kidney Dis
15:397—401, 1990
14. EGGERS PW: Mortality rates among dialysis patients in Medicare's
end stage renal disease program. Am J Kidney Dis 15:414-421, 1990
15. CHARRA B, CALEMARD E. RUFFET M, CHAZOT C, TERRAT JC,
VANEL T, LAURENT G: Survival as an index of adequacy of
dialysis. Kidney mt 41:1286—1291, 1992
16. HULL AR, PARKER III: Proceedings from the Morbidity, Mortality
and Prescription of Dialysis Symposium, Dallas, TX, September 15
to 17, 1989. Am J Kidney Dis 15:375—385, 1990
17. L0wRIE EG, LEW NL, HUANG WH: Race and diabetes as death
risk predictors in hemodialysis patients. Kidney mt 42:S22—S31,
1992
18. STAMLER R, FORD CE, STAMLER J: Why do lean hypertensives
have higher mortality rates than other hypertensives? Hypertension
17:553—564, 1991
19. KOPPLE JD: Nutritional management. Part 2. Chronic renal failure
(Chapt 80), in Textbook of Nephrology (2nd ed), edited by SG
MA55RY, RJ GLASSOCK, Baltimore, Williams & Wilkins, 1991, pp.
1344—1358
20. KJELLSTRAND CM, HYLANDER B, COLLINS AC: Mortality on
dialysis—On the influence of early start, patient characteristics,
and transplantation and acceptance rates. Am J Kidney Dis 15:483—
490, 1990
21. BERGSTROM J: Protein catabolic factors in patients on renal replace-
ment therapy. Blood Purif 3:215—236, 1985
22. KOPPLE JD, BERG R, HOUSER H, STEINMAN TI, TESCHAN P:
Nutritional status of patients with different levels of chronic renal
insufficiency. Kidney mt 36:S184—Sl94, 1989
23. HEALTH AND WELFARE STATISTICS ASSOCIATION: Health services
in Japan (Kokumin Eisei no Doko). Indices of Health and Welfare
(Kosei no Shihyo) 37:S79—S86, 1990
24. WOLCOTT DL, MAIDA CA, DIAMOND R, NISSENSON AR: Treat-
ment compliance in end-stage renal disease patients on dialysis. Am
J Nephrol 6:329—338, 1986
25. SCHOENFELD PY, HENRY RR, LAIRD NM, ROXE DM: Assessment
of nutritional status of the National Cooperative Dialysis Study
population. Kidney mt 23:S80—S88, 1983
26. LINDSAY RM, SPANNER E: A hypothesis: The protein catabolic
rate is dependent upon the type and amount of treatment in
dialyzed uremic patients. Am J Kidney Dis 13:382—389, 1989
27. DELMEZ IA, SLATOPOLSKY E: Hyperphosphatemia: Its conse-
quences and treatment in patients with chronic renal failure. Am J
Kidney Dis 19:303—317, 1992
28. CHARR.& B, CALEMARD E, CUCHE M, LAURENT G: Control of
hypertension and prolonged survival on maintenance hemodialysis.
Nephron 33:96—99, 1983
29. HARDY R, HAWKINS CM: The impact of selected indices of
antihypertensive treatment on all-case mortality. Am J Epidemiol
117:566—574, 1983
30. RUTAN GH, KULLER LH, NEATON JD, WENTWORTH DN, MC-
DONALD RH, SMITH WM: Mortality associated with diastOlic
hypertension and isolated systolic hypertension among men
screened for the Multiple Risk Factor Intervention trial. Circulation
77:504—514, 1988
31. UEDA K, OMAE T, HASUO Y, KIYOI-IARA Y, FUJII I, WADA J,
KATO I, KAWANO H, SHINKAWA A, OMURA T, FUJISHIMA M:
Prognosis and outcome of elderly hypertensives in a Japanese
community: Results from a long-term prospective study. J Hyper-
tens 6:991—997, 1988
32. CHURCHILL DN, TAYLOR W, CooK RJ, LAPLANTE MP, BARRE P,
CARTIER P, FAY WP, GOLDSTEIN MB, JINDAL K, MANDIN H,
MCKENZIE JK, MUIRHEAD N, PARFREY PS, POSEN GA, SLAUGH-
TER D, ULAN RA, WERB R: Canadian hemodialysis morbidity
study. Am J Kidney Dis 19:214—234, 1992
33. LINDNER A, CHARRA B, SHERRARD D, SCRIBNER B: Accelerated
atherosclerosis in prolonged maintenance hemodialysis. N Engi J
Med 290:697—701, 1974
34. ROSTAND SG, GRETES JC, KIRK KA, RUTSKY EA, ANDREOLI TE:
Ischemic heart disease in patients with uremia undergoing mainte-
nance hemodialysis. Kidney mt 16:600—611, 1979
35. VINCENTI F, AMEND WJ, ABELE J, FEDUSKA NJ, SALVATIERRA 0:
The role of hypertension in hemodialysis-associated atherosclero-
sis. Am J Med 68:363—369, 1980
36. WIZEMANN V. KRAMER W: Short-term dialysis—Long-term com-
plications. Ten years experience with short-duration renal replace-
ment therapy. Blood Purif 5:193—201, 1987
